SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Amended Form 8-K was filed by Hemispherx Biopharma, Inc. (Delaware) on July 12, 2000, reporting events occurring between May 3, 2000, and June 5, 2000. The filing addresses a change in the company's independent certifying accountant.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the transition of audit services.
Material Changes
- Resignation of Former Accountant: KPMG LLP resigned from its client-auditor relationship on May 3, 2000, following a decision by the Board and Audit Committee to seek a new firm.
- Engagement of New Accountant: On June 5, 2000, the company engaged BDO Seidman, LLP as its new Independent Accountants to audit consolidated financial statements and provide required professional services.
- Audit History: KPMG's reports for fiscal years ended December 31, 1998, and 1999, contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
- No Disagreements: There were no reportable events or disagreements between the Registrant and KPMG regarding accounting principles, practices, or disclosures during the two most recent fiscal years and the interim period through May 3, 2000.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, or specific risk factors beyond the standard disclosure of the auditor change. The company is required to file a subsequent Form 8-K within 10 business days of this filing to include a letter from KPMG stating whether they agree with the statements made in this report.
Investor Verification Checklist
- Verify the subsequent Form 8-K filing containing KPMG's response letter regarding the resignation.
- Confirm the scope of services and engagement terms with the new auditor, BDO Seidman, LLP.
- Review the most recent audited financial statements (1998 and 1999) to ensure no undisclosed issues exist despite the clean audit opinions.
- Monitor future filings for any restatements or qualifications that may arise from the change in accounting firms.